Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
520 participants
INTERVENTIONAL
2023-04-14
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
440 patients (subjects with swallowing disorders), spread over 4 centers and 80 healthy subjects spread over 2 centers will be recruited for the study in an interventional research study involving the prospective, multicentric and longitudinal.
Pharyngolaryngeal effectiveness will be measured from 6 indicators identified by examinations or reference tests grouped into 3 functions:
* swallowing: pharyngeal transport capacity (Yale Residue) and Penetration Aspiration Scale (PAS) rated by videofluoroscopy of swallowing (VFS) or flexible endoscopic evaluation of swallowing (FEES);
* airway protection: cough trigger (citric acid test) and cough power (peak expiratory flow);
* phonation: vocal efficiency (maximum phonation time) and velar efficiency (nasal scores).
The signals obtained from the 5 sensors will be annotated. Stochastic modelling based on hidden Markov models will be used initially and followed by the implementation of deep neural networks to model indicators. For the complication's prediction algorithm, deep neural networks will also be used to evaluate signal-based methods.
The expected benefits are to obtain automated recognition of pharyngeal-laryngeal effectiveness to diagnose swallowing disorders using objective and quantifiable indicators, non-invasive devices, to assess the severity of these disorders and to identify the risk of complications.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Translation and Validation of the Visual Analysis of Swallowing Efficiency and Safety Into European Portuguese
NCT06742034
Assessment of the Effects of Mental Practice on Tongue Strength in Brain-damaged Patients
NCT04615598
Correlation Between Montreal Cognitive Assessment and Voice Therapy Outcomes in the Aging Treatment- Seeking Population
NCT05187910
Task of Acoustic-phonetic Decoding on Anatomic Deficits in Paramedical Assessment of Speech Disorders for Patients Treated for Oral or Oropharyngeal Cancer
NCT04742998
A Systematic Investigation of Phonetic Complexity Effects on Articulatory Motor Performance in Progressive Dysarthria
NCT03613038
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Primary objective: From the signals of 5 non-invasive sensors, model a multidimensional scale of pharyngeal-laryngeal efficiency measuring the 3 main functions of pharyngeal-larynx: swallowing function (evaluated by pharyngeal transport and closure of the larynx) ; airway protection function (evaluated by cough reflex and cough power); phonation function (evaluated by voice and velar efficiency)
Secondary Objectives:
* Develop a diagnostic model of different physiopathological mechanisms of swallowing
* Determine an algorithm that can predict the severity of these disorders based on pharyngeal efficacy indicators
* Determine an algorithm capable of predicting the risk of complications from swallowing disorders, based on modelling pharyngeal effectiveness (primary objective) and clinical data
Study design: An interventional research study involving the prospective, multicentric and longitudinal human person to develop a scale of pharyngeal-laryngeal effectiveness measured from signals from 5 non-invasive sensors. The signals will be collected from each participant using the sensors (microphone, accelerometer, nasal cannula, surface EMG and oximeter). Algorithms will be developed from these signals to predict different indicators of pharyngeal-laryngeal efficiency measured by baseline tests. The study population will include patients with swallowing disorders (to identify pathological signal patterns) and healthy volunteers (to identify non-pathological physiological patterns of swallowing mechanisms).
440 patients (subjects with swallowing disorders), spread over 4 centers and 80 healthy subjects spread over 2 centers will be recruited for the study.
Research procedures
For patients with swallowing disorders:
During a hospital visit as part of their care pathway, patients with the criteria will be offered to participate in the research protocol. The subjects who have given their written consent will then carry out their assessment of the swallowing performed according to the available reference examination (videofluoroscopy or nasofibroscopy). In parallel, they will carry the following sensors: microphone, accelerometer, surface electromyography, nasal cannula and pulse oximeter. For research purposes, the subjects will also perform a cough and phonation test and questionnaires. Other data used are collected as part of routine care.
At the end of the assessment, the patient will receive management advice based on the reference exams and his medical record.
Each subject (or his caregiver) will be contacted by phone once a month for 6 months to monitor the occurrence of complications, The end of study visit at 6 months will be done either at the hospital with a new examination of the swallowing, by telephone, as medically indicated.
For healthy volunteers:
Only one visit is planned for the evaluation of the swallowing with the examination of nasofibroscopy and the installation of the sensors. The procedures (tests, examinations and questionnaires) will be identical to the data collection of the initial visit of patients with swallowing disorders)
Duration of the research: The first patient will be included from 2023. The inclusion period is 18 months. Patients will be monitored for 6 months (+/- 2 months) after inclusion Healthy volunteers will have one visit (estimated time: 2H) The total duration of the clinical study is expected to be 26 months
Data analysis: The characteristics of the subjects as well as the various clinical indicators of swallowing and their evolution during monitoring will be described. Development and validation algorithms to model the various pharyngo-laryngeal effectiveness indicators and predictive algorithms of swallowing disorders will be produced using statistical approaches and also using machine learning. The signals obtained from the 5 sensors will be annotated. The signals will be standardized and synchronized to allow the modelling of the sequences corresponding to the following events: swallowing of food, saliva, cough, throat clearing, speech, wet voice. Stochastic modelling based on hidden Markov models will be used initially and followed by the implementation of deep neural networks to model indicators. For the complication's prediction algorithm, deep neural networks will also be used to evaluate signal-based methods.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Experimental arm
Patients with swallowing disorders and healthy volunteers
Swallowing evaluation
For patients with swallowing disorders: assessment of the swallowing performed according to the available reference examination (videofluoroscopy or nasofibroscopy). In parallel, they will carry the following sensors: microphone, accelerometer, surface electromyography, nasal cannula and pulse oximeter. The subjects will also perform a cough and phonation test and questionnaires. Each subject (or his caregiver) will be contacted by phone once a month for 6 months to monitor the occurrence of complications. The end of study visit at 6 months will be done either at the hospital with a new examination of the swallowing, by telephone, as medically indicated.
For healthy volunteers: Only one visit is planned for the evaluation of the swallowing with the examination of nasofibroscopy and the installation of the sensors. The procedures (tests, examinations and questionnaires) will be identical to the data collection of the initial visit of patients with swallowing disorders)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Swallowing evaluation
For patients with swallowing disorders: assessment of the swallowing performed according to the available reference examination (videofluoroscopy or nasofibroscopy). In parallel, they will carry the following sensors: microphone, accelerometer, surface electromyography, nasal cannula and pulse oximeter. The subjects will also perform a cough and phonation test and questionnaires. Each subject (or his caregiver) will be contacted by phone once a month for 6 months to monitor the occurrence of complications. The end of study visit at 6 months will be done either at the hospital with a new examination of the swallowing, by telephone, as medically indicated.
For healthy volunteers: Only one visit is planned for the evaluation of the swallowing with the examination of nasofibroscopy and the installation of the sensors. The procedures (tests, examinations and questionnaires) will be identical to the data collection of the initial visit of patients with swallowing disorders)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Able to follow up by phone for 6 months or have a caregiver who can answer for them
* Affiliated subject or beneficiary of the social security system
* Consent to participate obtained in writing and signed by the subject or, if applicable, the next of kin/support person
* No swallowing disorder or discomfort (DHI score\<8)
* Affiliated subject or beneficiary of the social security system
* Signed Consent to Participate
* Skin lesion(s) at the neck
* Tracheotomy or tracheostomy (laryngectomy)
* Nasogastric probe
* Iodine allergy
* Asthma
* Refusal or any pathology incompatible with passing one of the two reference exams or the sensors used
* Any serious pathology (severe health or behavioral disorders) where, according to the investigator, this could expose participants to additional risks
* Legal protection (guardianship, curators, safeguarding of justice)
* Pregnant and lactating women
* Medical history may result in chronic (history of oral-rhino-laryngeal cancer or neurological disease) or temporary (upper respiratory tract infections) swallowing impairment
* Presence of swallowing disorder or discomfort (Deglutition Handicap Index score superior or equal to 8)
* Skin lesion(s) at the neck
* Tracheotomy or tracheostomy (laryngectomy)
* Nasogastric probe
* Iodine allergy
* Asthma
* Refusal or any pathology incompatible with passing one of the two reference exams or the sensors used
* Any serious pathology (severe health or behavioral disorders) where, according to the investigator, this could expose participants to additional risks
* Legal protection (guardianship, curators, safeguarding of justice)
* Pregnant and lactating women
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Research Agency, France
OTHER
Institut de Recherche en Informatique de Toulouse (IRIT)
UNKNOWN
Laboratoire parole et langage
UNKNOWN
Swallis Medical
INDUSTRY
University Hospital, Toulouse
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Virginie WOISARD, MD
Role: PRINCIPAL_INVESTIGATOR
University Hospital of Toulouse
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University hospital of Bordeaux
Bordeaux, , France
University hospital of Rouen
Rouen, , France
University Hospital of Toulouse
Toulouse, , France
University hospital of Tours
Tours, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Emmanuelle CUGY, MD
Role: primary
Eric VERIN, MD
Role: primary
Sylvain MORINIERE
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023-A00054-41
Identifier Type: OTHER
Identifier Source: secondary_id
RC31/22/0091
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.